Find a Cancer Clinical Trial for Your Child
Memorial Sloan Kettering conducts hundreds of clinical trials to improve care for people with many types of cancer. This includes more than 100 studies for children, teens, and young adults. Use this tool to browse our list of open clinical trials for young people. Each listing explains the purpose of the trial, who is eligible, and how to get more information.
New clinical trials are always opening. For more information and to find out about our latest studies, call 833-675-5437 or email us at [email protected].
Displaying 61–70 of 81 results.
-
The purpose of this study is to assess the safety and effectiveness of the investigational drug repotrectinib in children and young adults with solid tumors that have continued to grow or spread despite treatment. Repotrectinib works by targeting and blocking certain proteins that play a role in cancer growth. Some of these proteins are controlled by the ALK, ROS1, NTRK1, NTRK2, and NTRK3 genes. Researchers also think that combining repotrectinib with the chemotherapy drugs irinotecan and temozolomide may make the treatment more effective.
-
Many people who get chemotherapy experience a loss of their period (amenorrhea). They may have menopause-like symptoms such as insomnia, hot flashes, and anxiety. The condition also increases the risk of infertility.
-
Researchers want to see how well ulixertinib works in people with histiocytic neoplasms. Histiocytic neoplasms are rare diseases in which too many white blood cells called histiocytes build up in tissues and organs. This can cause damage to tissue or tumor(s) to form. The tumor(s) may be benign (not cancer) or malignant (cancer). There are different types of histiocytic neoplasms, including:
-
MSK researchers are studying a new CAR T cell therapy to treat acute myeloid leukemia (AML). They want to evaluate its safety and find the best dose of the new treatment. The adults and children in this study have AML that keeps growing even after treatment. The new CAR T cell therapy is called CD371-CAR-IL18.
-
The purpose of this study is to find the highest dose of the investigational drug PF-07799933 that can be given alone and in combination with binimetinib or cetuximab in people with advanced solid tumors that have continued to grow despite treatment and contain a mutation in the BRAF gene. A mutated BRAF gene makes a protein that sends signals to cancer cells to grow and divide. While some anti-cancer drugs only work for certain BRAF mutations, the investigational drug PF-07799933 may target all types of BRAF mutant proteins, blocking them from sending these signals and causing cancer cells to die.
-
Researchers in this study want to determine if combining the drug venetoclax with standard chemotherapy may be more effective than standard chemotherapy alone in children and adolescents with relapsed acute myeloid leukemia (AML). Venetoclax blocks Bcl-2, a protein that helps cancer cells to survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make other treatments more effective.
-
Researchers are seeking the best dose of CABA-201 to treat people with active idiopathic inflammatory myopathy (IIM). The people in this study have IIM, juvenile idiopathic inflammatory myopathy (JIIM), or myositis. With JIIM and some subtypes of IIM, B cells make the body to attack different tissues, causing inflammation and muscle weakness.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to see if adding cabozantinib to standard chemotherapy works better than chemotherapy alone for osteosarcoma. The people in this study include children, adolescents, and young adults with osteosarcoma that has not yet been treated.
-
Severe aplastic anemia is a serious condition where the bone marrow does not make the normal amount of blood cells. Bone marrow transplantation is one way to treat this disease. It has been reserved for people under age 40 with a related donor whose cells fully match theirs. However, advances have been made in bone marrow transplantation that make it an option for more people.